why choose us

First received: August 31, 2022

Clinical Trial: Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Allergic Fungal Rhinosinusitis

Study Type: INTERVENTIONAL


Official Title: A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosin

Brief Summary: The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS).Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages.Despite appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery, nasal polyps return frequently within months of surgery.Certain proteins made by the body called interleukins, appear to play a major role in the survival…

Read more